

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Aquarius Surgical Technologies Inc. (the "Issuer").

Trading Symbol: ASTI

Number of Outstanding Listed Securities: 19,048,265

Date: May 7, 2018

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

Two very influential clinical trials were successfully completed in April and both have led to additional opportunities for both marketing support and potential additional revenue growth.

The Benign Prostate Hyperplasia laser clinical trial, under the direction of the Chief of Urology of a university medical hospital in the northeast comprised several live clinical cases with both lateral fire and contact fiber technologies. All treatments were clinically successful in delivering immediate symptom relief and accomplishing the treatment objective in the absence of any contraindication, peri or post operatively. As a result of this successful trial, negotiations are underway with the university medical hospital regarding the purchase of equipment for the hospital as well as a joint venture implementing the technology and technique into the educational program for their residents as well as other clinicians interested in implementing the technology in their private offices and surgical centers.

The successful completion of the initial phase of the compact holmium laser for lithotripsy clinical trial, which took place under the direction of a Professor of Urology and Biomedical Engineering of another major university hospital in the northeast, has also lead to opportunity for revenue and marketing support. Negotiations are also underway with this university hospital for the purchase of this equipment for their internal use and through the holmium trial period, potential opportunities arose for the BPH laser which they have now expressed interest in evaluating for purchase as well.

Finally, the final reports required for FDA marketing approval for the C02 laser for gynecology are in the process of being assembled and will be resubmitted to the FDA this month, which is the final step of Issuer's responsibility relative to FDA 510 Clearance.

2. Provide a general overview and discussion of the activities of management.

Further to the above, management presented the corporate story to approximately 35 Brokers and high net worth investors on April 10, in Toronto, and to approximately 40 in Montreal on May 2.

The feedback has been encouraging, such that the earlier announced private placement to accredited investors has been increased in size from \$1,000,000 to \$2,600,000, subject to regulatory approval.

First closing in the amount of \$366,624 occurred on April 30. Management intends to further develop this initiative in the USA when cash flow and available working capital permits.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

None

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

None

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None

8. Describe the acquisition of new customers or loss of customers.

None

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

None

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None

11. Report on any labour disputes and resolutions of those disputes if applicable.

Not applicable

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds⁽¹⁾
Units (see below)	814,720	Private Placement	\$366,624 to be used for General Working Capital purposes
Agent’s Warrants (see below)	11,400	Agent’s commission on placement	n/a

(1) *State aggregate proceeds and intended allocation of proceeds.*

- **Each Unit comprises one fully paid non-assessable common share of the Issuer and One (1) Warrant, exercisable for a period of two years from the date of issue at a price of \$0.90. Each Warrant will entitle the holder to purchase One (1) fully paid non-assessable common share from the Treasury of the Company. Warrant Feature: Warrants have a “Callable” feature, empowering the Issuer to Call the Warrant for exercise at any time while they are outstanding if the average closing price of the stock on the market over a period of 20 trading days in any period of thirty consecutive trading days is at or above 216% of the respective exercise price of the Warrants. The Call procedure provides that that the Issuer may give Notice to Exercise within 30 days, after which date any unexercised Warrants will become void. All securities issued in the private placement are subject to a restrictive “hold period” of four months and one day from April 30, 2018, as provided for in applicable securities regulations.**
- **Each Agent’s Warrant, which is non-transferable, entitles the holder to acquire a Unit at the price of \$0.45 for a period expiring on April 30, 2020, subject to a similar Call Option in favour of the Issuer as described above in relation to the Units.**

15. Provide details of any loans to or by Related Persons.

None

16. Provide details of any changes in directors, officers or committee members.

None

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

No current changes

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated May 7, 2018

N. Gary Van Nest
Name of Director or Senior
Officer

Signed "Gary Van Nest"
Signature
Acting CEO
Official Capacity

Issuer Details Name of Issuer Aquarius Surgical Technologies Inc.	For Month End April 2018	Date of Report YY/MM/D 18/05/7
Issuer Address 89 Scollard Street		
City/Province/Postal Code Toronto, ON M5R 1G4	Issuer Fax No. (902)484-7599	Issuer Telephone No. (902) 496-7594
Contact Name Gary Van Nest	Contact Position Acting CEO	Contact Telephone No (647) 308-0685.
Contact Email Address gary@sinaltainvestments.com	Web Site Address www.surgicallasersinc.com	